// App-Quantinova.ai

SAT-546 : Monthly Pasireotide LAR Improves Urinary Free Cortisol (UFC) in Patients with Cushin-s Disease: Results from a Randomized, Double-Blind, Multicenter, Phase III Study

Researchers

Presenter

  • Stephan Petersenn

Principal Investigators

  • Beverly M.K. Biller

  • Fernanda Arnaldez

  • Michael Roughton

  • Shoba Ravichandran

  • John Newell-Price

Medical Centers

  • ENDOC Center for Endocrine Tumors, Hamburg, Germany

  • University of Sheffield, Sheffield, United Kingdom

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Massachusetts General Hospital, Boston, MA

Locations

  • United States

  • Germany

  • United Kingdom

  • Canada

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Hyperglycemia

  • Acromegaly

  • Venous thrombosis

Biomarkers

  • Protein Tyrosine Phosphatase, Receptor Type F

Drug/Treatment

  • Pasireotide

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved